small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search

Capabilities 44 results

Practice Area

Antitrust/Competition

Practice Area

Class Actions & Group Litigation

Winston has developed a consistent record of success handling class action cases in state and federal courts. The practice is anchored by seasoned class action lawyers, many of whom have been recognized by Chambers USA and other ranking organizations as being top practitioners in their field. Our clients rely on us to steer them through class action matters by drawing on the firm’s significant experience in resolving complex litigation using creative and aggressive arguments, across a broad range of class, collective, coordinated, and mass actions, as well multidistrict litigation. We also have succeeded at trial in several class actions—a rare occurrence....Read more

Industry

Life Sciences

Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations....Read more

Experience 113 results

Experience

|

January 19, 2026

Winston Advises smartTrade Technologies Group on the Acquisition of kACE

A cross-border team from advised smartTrade Technologies Group (“smartTrade”), a leading provider of multi-asset electronic trading and payments solutions, on its acquisition of kACE Financial (“kACE”), formerly known as Fenics, a well-established provider of technology solutions for FX and interest rate derivatives pricing, analytics, and workflow management....Read more

Experience

|

December 3, 2025

US Tiger Securities Announced IPO

Winston & Strawn LLP is serving as U.S. securities counsel to US Tiger Securities, Inc., a full-service broker/dealer, in connection with the $10,000,000 initial public offering of SMJ International Holdings Inc., a Singapore-based premium flooring specialist. The Company priced 2,500,000 Class A ordinary shares at US$4.00 per share. The Class A ordinary shares are expected to begin trading on the NYSE American under the ticker symbol “SMJF” on December 4, 2025....Read more

Experience

|

October 1, 2025

AA Mission Acquisition Corp. II - Initial Public Offering

Winston & Strawn LLP represented AA Mission Acquisition Corp. II, a blank check company, in the recent closing of its $100 million Initial Public Offering (IPO). The offering consisted of 10,000,000 units priced at $10.00 per unit, before deducting underwriting discounts and estimated offering expenses. The units began trading on the New York Stock Exchange (NYSE) under the ticker symbol “YCY.U” on October 1, 2025....Read more
View All Experience

Insights & News 842 results

Benefits Blast

|

February 17, 2026

|

9 Min Read

New Transparency Requirements for Pharmacy Benefit Managers: What Group Health Plan Sponsors Need to Know

Recent developments at the federal legislative and regulatory levels signal a significant shift toward greater transparency requirements in the pharmacy benefit management (PBM) industry.

In the Media

|

February 17, 2026

|

2 Min Read

Scott Naidech Discusses CV Transaction Risks with Private Equity Law Report

Winston & Strawn partner Scott Naidech was quoted in a Private Equity Law Report article discussing key takeaways for sponsors to consider as they undertake continuation vehicle (CV) transactions following a complaint filed in Delaware Court of Chancery that highlights the potential risks when a fund sponsor seeks to push through a CV transaction over the objection of existing investors....Read more

News

|

February 13, 2026

|

7 Min Read

UK Crypto Regulation Moves Forward: Admissions & Disclosures and Market Abuse for Cryptoassets – Key Takeaways from FCA CP25/41

Our latest Client Alert on FCA CP25/41, outlining the UK’s proposed Admissions & Disclosures regime and new Market Abuse Regime for Cryptoassets (MARC).

The proposals introduce enhanced gatekeeper responsibilities for Cryptoasset Trading Platforms, a new Qualifying Cryptoasset Disclosure Document (QCDD) framework with associated liability provisions, retail investor withdrawal rights in certain circumstances, a tailored approach for UK-issued stablecoins, and a bespoke market abuse regime for cryptoassets.

With the consultation closing on 12 February 2026 and final rules expected later this year, firms should begin assessing potential operational and governance impacts.

View All Insights & News

Other Results 32 results

Site Content

What Is the Price Range in an IPO?

The price range is a proposed price per share range for the IPO within which investors can bid for shares and which is often printed on the cover page of a preliminary prospectus. The price range has a minimum price, known as the floor price, and a maximum price, known as the cap price....Read more

Site Content

What Is the BPCIA?

Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) to provide an abbreviated pathway for biosimilars to gain FDA approval through submission of an abbreviated Biologics License Application (aBLA)....Read more

Site Content

What Is Dilution?

Dilution refers to the reduction in an existing shareholder’s ownership percentage of a company when the company issues additional shares. Dilution in an IPO results from a disparity between the public offering price in an IPO and the effective cash cost to persons who acquired shares prior to the IPO. Dilution is disclosed in the registration statement in a dilution table....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2026. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising